CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
USA - NASDAQ:CORT - US2183521028 - Common Stock
73.72 USD
+0.66 (+0.9%)
73.72 USD
0 (0%)
Overall CORT gets a fundamental rating of 7 out of 10. We evaluated CORT against 192 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make CORT suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
Each year in the past 5 years CORT has been profitable.
In the past 5 years CORT always reported a positive cash flow from operatings.
1.2 Ratios
CORT's Return On Assets of 16.67% is amongst the best of the industry. CORT outperforms 96.35% of its industry peers.
With an excellent Return On Equity value of 21.02%, CORT belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
CORT has a better Return On Invested Capital (13.39%) than 91.67% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is above the industry average of 15.37%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(13.39%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.67% | ||
| ROE | 21.02% | ||
| ROIC | 13.39% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT has a Profit Margin of 18.66%. This is amongst the best in the industry. CORT outperforms 92.71% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
CORT has a better Operating Margin (14.24%) than 84.90% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
The Gross Margin of CORT (98.37%) is better than 97.92% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.24% | ||
| PM (TTM) | 18.66% | ||
| GM | 98.37% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CORT is creating value.
CORT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CORT has less shares outstanding
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CORT has an Altman-Z score of 30.64. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT has a Altman-Z score of 30.64. This is amongst the best in the industry. CORT outperforms 94.27% of its industry peers.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 30.64 |
ROIC/WACC1.53
WACC8.76%
2.3 Liquidity
CORT has a Current Ratio of 3.06. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.06, CORT perfoms like the industry average, outperforming 57.81% of the companies in the same industry.
CORT has a Quick Ratio of 2.98. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT's Quick ratio of 2.98 is in line compared to the rest of the industry. CORT outperforms 58.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.06 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
The earnings per share for CORT have decreased strongly by -30.16% in the last year.
CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
The Revenue has grown by 39.94% in the past year. This is a very strong growth!
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)39.94%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
3.2 Future
Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 54.86% on average per year.
The Revenue is expected to grow by 30.93% on average over the next years. This is a very strong growth
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.86%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y30.94%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 83.77, CORT can be considered very expensive at the moment.
CORT's Price/Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 77.60% of the companies in the same industry.
CORT is valuated expensively when we compare the Price/Earnings ratio to 25.83, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 36.64, CORT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 70.83% of the companies listed in the same industry.
CORT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 32.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 83.77 | ||
| Fwd PE | 36.64 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 77.60% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.09 | ||
| EV/EBITDA | 69.09 |
4.3 Compensation for Growth
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 64.99% in the coming years.
PEG (NY)N/A
PEG (5Y)8.62
EPS Next 2Y27.38%
EPS Next 3Y64.99%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
73.72
+0.66 (+0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.03%
Inst Owner Change0.52%
Ins Owners6.58%
Ins Owner Change-0.01%
Market Cap7.77B
Revenue(TTM)675.04M
Net Income(TTM)133.66M
Analysts82
Price Target137.93 (87.1%)
Short Float %11%
Short Ratio11.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.3%
Min EPS beat(2)16.96%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)17.73%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)18.86%
EPS beat(12)9
Avg EPS beat(12)14.75%
EPS beat(16)12
Avg EPS beat(16)12.32%
Revenue beat(2)0
Avg Revenue beat(2)-8.89%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-4.4%
Revenue beat(4)1
Avg Revenue beat(4)-5.99%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)5
Avg Revenue beat(8)-1.83%
Revenue beat(12)6
Avg Revenue beat(12)-1.82%
Revenue beat(16)7
Avg Revenue beat(16)-2.2%
PT rev (1m)-0.02%
PT rev (3m)-2.19%
EPS NQ rev (1m)-19.4%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)-7.64%
EPS NY rev (3m)-27.59%
Revenue NQ rev (1m)-2.34%
Revenue NQ rev (3m)-11.72%
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-5.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 83.77 | ||
| Fwd PE | 36.64 | ||
| P/S | 10.85 | ||
| P/FCF | 43.09 | ||
| P/OCF | 42.63 | ||
| P/B | 12.22 | ||
| P/tB | 12.22 | ||
| EV/EBITDA | 69.09 |
EPS(TTM)0.88
EY1.19%
EPS(NY)2.01
Fwd EY2.73%
FCF(TTM)1.71
FCFY2.32%
OCF(TTM)1.73
OCFY2.35%
SpS6.8
BVpS6.03
TBVpS6.03
PEG (NY)N/A
PEG (5Y)8.62
Graham Number10.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.67% | ||
| ROE | 21.02% | ||
| ROCE | 15.52% | ||
| ROIC | 13.39% | ||
| ROICexc | 28.18% | ||
| ROICexgc | 28.18% | ||
| OM | 14.24% | ||
| PM (TTM) | 18.66% | ||
| GM | 98.37% | ||
| FCFM | 25.18% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 193.83% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 176.99% | ||
| Profit Quality | 134.88% | ||
| Current Ratio | 3.06 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z | 30.64 |
F-Score6
WACC8.76%
ROIC/WACC1.53
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.86%
Revenue 1Y (TTM)39.94%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y30.94%
EBIT growth 1Y-20.33%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-34.64%
EBIT Next 3Y41.42%
EBIT Next 5Y19.15%
FCF growth 1Y33.84%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y34.76%
OCF growth 3Y5.66%
OCF growth 5Y7.79%
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CORT.
What is the valuation status for CORT stock?
ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.
Can you provide the profitability details for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.
What is the financial health of CORCEPT THERAPEUTICS INC (CORT) stock?
The financial health rating of CORCEPT THERAPEUTICS INC (CORT) is 8 / 10.